Perinatal Outcome Following Third Trimester Exposure to Paroxetine

Abstract

When used near term, paroxetine is associated with a high rate of neonatal complications, possibly caused by its common discontinuation syndrome.

Behavioral and Developmental Changes in Rats with Prenatal Exposure of Mirtazapine

“…The present study supports the earlier report [14, 15], which suggest that the children exposed with serotonin reuptake inhibitors, displayed subtle changes in motor development and in motor movement control. In addition, the various studies [16, 17] suggest that the prenatal exposure of most of the antidepressants affects on motor development of offspring.…”

A pilot study of newer antidepressant concentrations in cord and maternal serum and possible effects in the neonate

“…Mildly increased NAS were seen early after birth in 2 of the 4 neonates whose mothers were taking fluoxetine, in one of the twins of a mother who was taking paroxetine, but in none of the neonates whose mothers took sertraline or venlafaxine. Thus for paroxetine, our two cases do not mirror the plethora of previous case reports of adverse effects (Bhatt and Coombs, 2001;Dahl et al, 1997;Nijhuis et al, 2001;Stiskal et al, 2001), or a recent study (n=55) (Costei et al, 2002) in which 22 % of neonates had adverse effects. For example, fluoxetine and norfluoxetine were present in all four infants at day 5, while only two had symptoms.…”

Antidepressant use in pregnancy: a critical review focused on risks and controversies

“…Another hospital based cohort study found PNAS in 30% of infants exposed to SSRIs (116). This rate of 30% is higher than found by Costei et al (22%) (102), and Hendrick et al (10.5%) (55) but very similar to that found by Chambers et al (31.5%) (35) and Oberlander et al (30%) (104). The data collected by Costei may not represent the true rate as data were collected later after delivery and cases may have been missed.…”